TOT BIOPHARM International Company Limited (1875.HK)

HKD 2.04

(-0.49%)

EBITDA Summary of TOT BIOPHARM International Company Limited

TOT BIOPHARM International Company Limited's latest annual EBITDA in 2023 was 10.44 Million CNY , up 826.3% from previous year.
TOT BIOPHARM International Company Limited's latest quarterly EBITDA in 2024 Q2 was 61.76 Million CNY , down 0.0% from previous quarter.
TOT BIOPHARM International Company Limited reported an annual EBITDA of -5.4 Million CNY in 2022, up 98.46% from previous year.
TOT BIOPHARM International Company Limited reported an annual EBITDA of -224.51 Million CNY in 2021, up 14.23% from previous year.
TOT BIOPHARM International Company Limited reported a quarterly EBITDA of N/A for 2023 FY, up 826.3% from previous quarter.
TOT BIOPHARM International Company Limited reported a quarterly EBITDA of 15.75 Million CNY for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of TOT BIOPHARM International Company Limited (2023 - 2017)

Historical Annual EBITDA of TOT BIOPHARM International Company Limited (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	10.44 Million CNY	826.3%
2022	-5.4 Million CNY	98.46%
2021	-224.51 Million CNY	14.23%
2020	-254.71 Million CNY	-6.24%
2019	-240.07 Million CNY	-8.42%
2018	-221.41 Million CNY	-138.68%
2017	-134.91 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	61.76 Million CNY	0.0%
2023 FY	- CNY	826.3%
2023 Q4	15.75 Million CNY	0.0%
2023 Q2	2 Million CNY	0.0%
2022 FY	- CNY	98.46%
2022 Q4	-14.49 Million CNY	0.0%
2022 Q2	10.06 Million CNY	0.0%
2021 Q2	-100.51 Million CNY	0.0%
2021 Q4	-123.68 Million CNY	0.0%
2021 FY	- CNY	14.23%
2020 Q4	-148.41 Million CNY	0.0%
2020 FY	- CNY	-6.24%
2020 Q2	-114.1 Million CNY	0.0%
2019 Q2	-99.13 Million CNY	0.0%
2019 Q4	-148.2 Million CNY	0.0%
2019 FY	- CNY	-8.42%
2018 Q2	-62.55 Million CNY	0.0%
2018 FY	- CNY	-138.68%
2018 Q1	-62.55 Million CNY	0.0%
2018 Q4	-67.41 Million CNY	0.0%
2017 Q2	-33.72 Million CNY	0.0%
2017 Q4	-62.55 Million CNY	0.0%
2017 Q1	-33.72 Million CNY	0.0%
2017 FY	- CNY	0.0%
2016 Q4	-33.72 Million CNY	0.0%

Peer EBITDA Comparison of TOT BIOPHARM International Company Limited

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	88.549%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	97.854%